Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 705564 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs BI 705564 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment as substance discontinued.
- 11 Dec 2018 Planned End Date changed from 4 May 2019 to 2 Sep 2019.
- 11 Dec 2018 Planned primary completion date changed from 30 Apr 2019 to 12 Aug 2019.